Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder.
J J Sramek, R E Robinson, A Suri, N R Cutler
Index: J. Clin. Psychopharmacol. 15(1) , 20-2, (1995)
Full Text: HTML
Abstract
The purpose of this study was to assess the anxiolytic effect of MDL 11,939, a selective 5-HT2 receptor antagonist, in patients with generalized anxiety disorder. After a 1-week placebo lead-in period, 72 healthy male outpatients meeting DSM-III-R criteria for generalized anxiety disorder were randomized to MDL 11,939, 32 mg thrice daily (N = 37), or placebo (N = 35) for 6 weeks. At the end of treatment, MDL 11,939 showed a 7.2-point (30%) decrease in Hamilton Rating Scale for Anxiety scores compared with a 5.7-point (23%) decrease with placebo, but the difference was not significant (p > 0.05). The incidence of adverse events between treatments was similar. MDL 11,939 was well tolerated but did not demonstrate significant anxiolytic effects in this pilot study.
Related Compounds
Related Articles:
2004-04-01
[Psychopharmacology 172(4) , 435-42, (2004)]
1999-01-01
[Psychopharmacology 141 , 162, (1999)]
2008-11-01
[Psychopharmacology 201(1) , 55-66, (2008)]
2012-08-01
[Behav. Neurosci. 126(4) , 530-7, (2012)]
2007-10-01
[J. Pharmacol. Exp. Ther. 323(1) , 327-35, (2007)]